UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

______________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2013

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION
(Translation of registrant’s name into English)

48^th Floor, Bank of China Tower
1 Garden Road
Central
                    Hong Kong S.A.R.                    
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                     Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨                     No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to confirm these statements to actual results, unless required by law.

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; compliance with restrictive debt covenants under the Company’s senior convertible notes; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission.

Results of Operations and Financial Condition

Following this cover page are the preliminary unaudited condensed consolidated financial results for the three months and year ended March 31, 2013 of the Company.

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31, 2012 and 2013

	March 31,		March 31,
	2012		2013
	RMB		RMB		US$
	(in thousands except share data)
ASSETS
Current assets
Cash and cash equivalents		794,311		1,494,099		240,565
Accounts receivable, less allowance for doubtful accounts (March 31, 2012: RMB13,916; March 31, 2013: RMB14,112)		79,012		73,076		11,766
Inventories		6,666		10,265		1,652
Prepaid expenses and other receivables		11,561		11,602		1,868
Trading securities		354		-		-
Debt issuance costs		-		3,678		592
Deferred tax assets		5,268		5,454		878
Total current assets		897,172		1,598,174		257,321
Property, plant and equipment, net		267,862		468,272		75,397
Non-current prepayments		2,863		212,633		34,236
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2012: RMB38,628; March 31, 2013: RMB36,361)		254,236		249,370		40,152
Inventories		34,651		39,730		6,396
Intangible assets, net		129,791		125,170		20,154
Available-for-sale equity securities		98,199		88,404		14,234
Other investment		134,363		189,129		30,452
Debt issuance costs		-		11,667		1,879
Deferred tax assets		5,013		3,727		600
Total assets		1,824,150		2,986,276		480,821
LIABILITIES
Current liabilities
Bank loan		45,000		50,000		8,050
Accounts payable		6,343		9,890		1,592
Accrued expenses and other payables		33,351		84,006		13,527
Deferred revenue		106,110		172,328		27,747
Amounts due to related parties		360		11,241		1,810
Income tax payable		5,943		4,983		802
Total current liabilities		197,107		332,448		53,528
Convertible notes		-		751,781		121,044
Non-current deferred revenue		306,534		530,258		85,377
Other non-current liabilities		60,420		107,158		17,254
Deferred tax liabilities		24,462		23,168		3,730
Total liabilities		588,523		1,744,813		280,933

EQUITY
Shareholders’ equity
Ordinary shares
- US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued
and outstanding as of March 31, 2012 and 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31, 2013	50	50		8
Additional paid-in capital	865,654	798,221		128,522
Treasury stock, at cost (March 31, 2012: nil; March 31, 2013: 136,899 shares)	-	(2,815	)	(453	)
Accumulated other comprehensive income	26,057	18,256		2,939
Retained earnings	310,973	423,420		68,175
Total shareholders’ equity	1,202,734	1,237,132		199,191
Non-controlling interests	32,893	4,331		697
Total equity	1,235,627	1,241,463		199,888
Total liabilities and equity	1,824,150	2,986,276		480,821

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Year ended March 31, 2012 and 2013

	Three months ended March 31,									Year ended March 31,
	2012			2013						2012			2013
	RMB			RMB			US$			RMB			RMB			US$
	(in thousands except share data)
Revenues		99,778			133,011			21,417			380,490			526,123			84,711
Direct costs		(23,330	)		(26,907	)		(4,332	)		(86,658	)		(106,621	)		(17,167	)
Gross profit		76,448			106,104			17,085			293,832			419,502			67,544
Operating expenses
Research and development		(1,953	)		(2,249	)		(362	)		(7,615	)		(8,459	)		(1,362	)
Sales and marketing		(16,567	)		(26,116	)		(4,205	)		(61,678	)		(93,684	)		(15,084	)
General and administrative		(23,086	)		(26,992	)		(4,346	)		(89,696	)		(108,045	)		(17,396	)
Total operating expenses		(41,606	)		(55,357	)		(8,913	)		(158,989	)		(210,188	)		(33,842	)
Operating income		34,842			50,747			8,172			134,843			209,314			33,702
Other income/(expense), net
Interest income		3,411			4,002			644			13,432			15,064			2,425
Interest expense		(896	)		(22,070	)		(3,553	)		(3,287	)		(70,097	)		(11,286	)
Exchange gain/(loss)		33			(25	)		(4	)		(1,343	)		(984	)		(158	)
Dividend income		-			-			-			7,217			4,685			754
Others		823			924			149			737			203			33
Total other income/(expense), net		3,371			(17,169	)		(2,764	)		16,756			(51,129	)		(8,232	)
Income before income tax		38,213			33,578			5,408			151,599			158,185			25,470
Income tax expense		(6,597	)		(10,483	)		(1,688	)		(9,634	)		(38,543	)		(6,206	)
Net income		31,616			23,095			3,720			141,965			119,642			19,264
Net income attributable to non-controlling interests		(2,377	)		(67	)		(11	)		(9,985	)		(7,195	)		(1,158	)
Net income attributable to the Company		29,239			23,028			3,709			131,980			112,447			18,106
Net income per share:
Attributable to ordinary shares
- Basic		0.40			0.32			0.05			1.79			1.49			0.24
- Diluted		0.40			0.32			0.05			1.79			1.49			0.24
Other comprehensive income
- Net effect of foreign currency translation, net of nil tax		(604	)		2,936			473			(1,653	)		1,296			209
- Net unrealized gain/(loss) in available-for-sale equity
securities, net of nil tax		58,055			12,023			1,936			46,587			(9,120	)		(1,468	)
Comprehensive income		89,067			38,054			6,129			186,899			111,818			18,005
Comprehensive income attributable to non-controlling
interests		(2,427	)		(67	)		(11	)		(10,282	)		(7,172	)		(1,155	)
Comprehensive income attributable to the Company		86,640			37,987			6,118			176,617			104,646			16,850

Other Events

On June 18, 2013, the Company issued a press release announcing preliminary unaudited condensed consolidated financial results for the three months and year ended March 31, 2013. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.	Description
99.1	Press Release, dated June 18, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHINA CORD BLOOD CORPORATION
By:	/s/ Albert Chen
Name:	Albert Chen
Title:	Chief Financial Officer

Dated: June 18, 2013